Table III.

Prolonged survival times among mice with established pulmonary tumors after Tc1 or Tc2 effector cell therapya

Therapy (i.v.)Mean Survival Time ± SEM (Days)% Increase in Mean Survival Timeb
Tc1-day 745.7 ± 1.6∗,∗∗66.8
Tc2-day 745.2 ± 2.0∗,∗∗64.9
Tc1-day 1437.5 ± 1.2∗36.9
Tc2-day 1434.6 ± 0.7∗26.3
None27.4 ± 0.8
  • a Mice (n = 10/group) were injected i.v. with 5 × 105 B16-OVA tumor cells. Tc1 or Tc2 effector cells were adoptively transferred into mice bearing established 7-day (early tumor development) or 14-day (late tumor development) metastases.

  • b Percent increase in the mean survival times (MST) for each group was calculated by (Treated MST − nontreated MST/nontreated MST) × 100. p value for treated animals vs untreated animals: ∗, p < 0.001; p value for day 7-treated animals vs day 14-treated animals: ∗∗, p < 0.002.